Clinical Trials Logo

Locally Advanced Solid Tumor clinical trials

View clinical trials related to Locally Advanced Solid Tumor.

Filter by:

NCT ID: NCT06416007 Not yet recruiting - Cancer Clinical Trials

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

NCT ID: NCT06415487 Not yet recruiting - Clinical trials for Metastatic Solid Tumor

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

NCT ID: NCT06349408 Not yet recruiting - Clinical trials for Locally Advanced Solid Tumor

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Start date: May 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. It includes a Phase 1 section to identify Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of IBI3001, and a Phase 2 section to explore and confirm the efficacy, safety and tolerability of IBI3001 at its RP2D.

NCT ID: NCT06184035 Recruiting - Solid Tumor Clinical Trials

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Tumorad
Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid tumors who have no standard of care treatment options. [177Lu]Lu-SN201 is a radiolabeled, nanomedical investigational medicinal product (IMP) whose mechanism of delivery is based on the Enhanced Permeability and Retention (EPR) effect.

NCT ID: NCT06028724 Recruiting - Breast Cancer Clinical Trials

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)

POPCORN
Start date: May 26, 2023
Phase:
Study type: Observational

The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. It is used to identify potential circulating dynamic biomarkers of treatment sensitivity or resistance in a real word multi-pathology evaluation. In this way, defining the mutational status of clinical relevance genes in real world, as a predictive biomarker to identify those patients most likely to benefit from target therapy, offers the potential to optimize access to further therapies. The aim of this study is to evaluate the real-world prevalence of clinically useful mutations in patients who are receiving therapy for advanced and locally advanced solid tumor through liquid biopsy.

NCT ID: NCT05919537 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Start date: September 6, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

NCT ID: NCT05919264 Recruiting - Cancer Clinical Trials

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Start date: May 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.

NCT ID: NCT05828277 Withdrawn - Clinical trials for Metastatic Solid Tumor

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Start date: July 28, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.

NCT ID: NCT05769075 Recruiting - Clinical trials for Metastatic Solid Tumor

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Start date: April 20, 2023
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.

NCT ID: NCT05732831 Recruiting - Clinical trials for Locally Advanced Solid Tumor

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Start date: May 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 159 participants.